The role of mitochondria in protection of the heart by preconditioning  by Halestrap, Andrew P. et al.
Biochimica et Biophysica Acta 1767 (2007) 1007–1031
www.elsevier.com/locate/bbabioReview
The role of mitochondria in protection of the heart by preconditioning
Andrew P. Halestrap ⁎, Samantha J. Clarke, Igor Khaliulin
Department of Biochemistry and Bristol Heart Institute, University of Bristol, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK
Received 23 April 2007; received in revised form 18 May 2007; accepted 23 May 2007
Available online 2 June 2007Abstract
A prolonged period of ischaemia followed by reperfusion irreversibly damages the heart. Such reperfusion injury (RI) involves opening of the
mitochondrial permeability transition pore (MPTP) under the conditions of calcium overload and oxidative stress that accompany reperfusion.
Protection from MPTP opening and hence RI can be mediated by ischaemic preconditioning (IP) where the prolonged ischaemic period is
preceded by one or more brief (2–5 min) cycles of ischaemia and reperfusion. Following a brief overview of the molecular characterisation and
regulation of the MPTP, the proposed mechanisms by which IP reduces pore opening are reviewed including the potential roles for reactive
oxygen species (ROS), protein kinase cascades, and mitochondrial potassium channels. It is proposed that IP-mediated inhibition of MPTP
opening at reperfusion does not involve direct phosphorylation of mitochondrial proteins, but rather reflects diminished oxidative stress during
prolonged ischaemia and reperfusion. This causes less oxidation of critical thiol groups on the MPTP that are known to sensitise pore opening to
calcium. The mechanisms by which ROS levels are decreased in the IP hearts during prolonged ischaemia and reperfusion are not known, but
appear to require activation of protein kinase Cε, either by receptor-mediated events or through transient increases in ROS during the IP protocol.
Other signalling pathways may show cross-talk with this primary mechanism, but we suggest that a role for mitochondrial potassium channels is
unlikely. The evidence for their activity in isolated mitochondria and cardiac myocytes is reviewed and the lack of specificity of the
pharmacological agents used to implicate them in IP is noted. Some K+ channel openers uncouple mitochondria and others inhibit respiratory
chain complexes, and their ability to produce ROS and precondition hearts is mimicked by bona fide uncouplers and respiratory chain inhibitors.
IP may also provide continuing protection during reperfusion by preventing a cascade of MPTP-induced ROS production followed by further
MPTP opening. This phase of protection may involve survival kinase pathways such as Akt and glycogen synthase kinase 3 (GSK3) either
increasing ROS removal or reducing mitochondrial ROS production.
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The heart is one of the most energy demanding tissues in the
body and is totally dependent upon oxidative phosphorylation
to supply the large amount of ATP required for beat-by-beat
contraction and relaxation. If the blood flow to the heart is
impaired (ischaemia), as occurs when a blood clot occludes a
coronary artery (coronary thrombosis) or where cardiac surgery
requires the heart to be disconnected from the blood supply, the
source of oxygen is removed leading to the cessation of
oxidative phosphorylation. This causes tissue ATP and creatine
phosphate concentrations to decrease with a concomitant rise in
ADP, AMP and Pi concentrations. Although glycolysis is
activated, it is unable to meet the demand of the beating heart
for ATP. Consequently, the heart rapidly ceases to beat as the
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combined with the decreasing pH that accompanies the
accumulation of glycolytic lactic acid [1–3]. The heart can
usually survive a short period of ischaemia and then recover
upon reperfusion. Although the performance of the heart may be
impaired initially (stunning), given time recovery is complete.
However, if the period of ischaemia is too long, the tissue
becomes irreversibly damaged. Hence, if the heart is to be
salvaged, it is important to restore the blood flow as soon as
possible. Yet, paradoxically, such reperfusion can exacerbate
the damage occurring during the ischaemic period. This is
known as reperfusion injury and is accompanied by enzyme
release and morphological changes characteristic of necrosis
[1–3]. The extent of damage can be visualised as an area of
necrotic tissue known as the infarct whose area can be
determined to provide a quantitative measure of injury.
Quantification of damage may also be provided by measuring
the release of intracellular proteins such as lactate dehydrogen-
ase or troponin I [4]. In addition to the necrotic cell death that
represents the major damage to the reperfused heart there is also
evidence that some myocytes around the periphery of the infarct
die by apoptosis [5,6]. Understanding the causes of reperfusion
injury and devising ways of preventing it is of major clinical
importance in cardiac surgery and the treatment of coronary
thrombosis.
There is increasing evidence that mitochondrial dysfunction
plays a central role in mediating both the necrotic and apoptotic
components of reperfusion injury, and that one of the most
effective ways of protecting hearts from such injury, known as
ischaemic preconditioning (IP), acts to attenuate this [1,3,7–
10]. This review will address the causes of reperfusion injury,
emphasising the role of the mitochondrial permeability
transition pore (MPTP) and prevention of its opening by IP.
The proposed signalling mechanisms through which IP may
exert its effects will be discussed, including the proposed role of
mitochondrial potassium channels which has been a major but
controversial area of research (see [11–13]. However, first it is
necessary to explain the phenomenon of preconditioning.
2. The phenomenon of ischaemic preconditioning
Ischaemic preconditioning (IP) involves exposing the heart
to brief periods of ischaemia (typically 2–5 min) interspersed
with periods of normal perfusion prior to the prolonged
ischaemia initiated within an hour of the preconditioning
protocol. This protocol was first shown to offer strong
protection against reperfusion injury in the dog heart by
Murry et al. in 1986 [14] and has since been confirmed in all
species investigated, including humans [15–17]. However, it
should be noted that significant reduction in infarct size only
occurs when the optimal duration for the test period of ischemia
is chosen and is lost if the ischaemic period is too long.
Preconditioned hearts exhibit a smaller infarct size and
intracellular enzyme release (indicators of necrotic cell death)
and fewer arrhythmias [14,18], whilst contractile function is
preserved [19]. Typically, 2–3 brief (2–5 min) cycles of
ischaemia and reperfusion are used in IP, there being littleadvantage of additional cycles [15]. If ischaemia is initiated
more than 1–2 h after the preconditioning protocol, protection is
lost but re-emerges again after about 24 h and lasts for up to 3
days. This is termed the second window of preconditioning
[15,20–22]. A wide variety of drugs that activate different
signalling pathways thought to be involved in mediating IP (see
Section 6) can also induce protection and thus preconditioning
is often used as a generic term to encompass any protocol
applied before prolonged ischaemia that protects the heart
during reperfusion. Not to be confused with such precondition-
ing is a more recently described phenomenon known as post-
conditioning. Here hearts are given several very brief ischaemic
interludes (10 s) during the early phase of reperfusion which
also improves the recovery of the heart and reduces infarct size
[23–25]. This protocol has considerable clinical potential since
intermittent reperfusion can be induced during angioplasty prior
to permanent restoration of blood flow. It is beyond the scope of
this review to consider the similarities and differences between
preconditioning and postconditioning in any detail. However,
many of the mechanisms and signalling pathways mediating
protection are thought to be the same [25] and where effects on
mitochondria have been demonstrated in postconditioning they
will be noted.
3. Causes of reperfusion injury
Increases in cellular [Ca2+] and reactive oxygen species
(ROS), initiated in ischaemia and then amplified upon
reperfusion, are thought to be the main causes of reperfusion
injury. Mitochondria are involved both in the production of
ROS and as targets for the damaging action of both ROS and
calcium [1,3,9,26].
3.1. Damage occurring in ischaemia (Reviewed in [1;3;26])
During ischaemia, the increased rate of glycolysis causes
lactic acid to accumulate and the intracellular pH (pHi) to drop
rapidly. This activates the Na+/H+ antiporter as the cell
endeavours to restore pHi. However, the rapidly declining
ATP concentrations cause inhibition of the Na/K ATPase and
lead to a rise in intracellular [Na+]. This in turn reduces the
ability of the cell to restore its pHi and increases intracellular
[Ca2+] since the Na+/Ca2+ antiporter that usually pumps Ca2+
out of the cell, is inhibited or reversed. The conversion of ATP
to ADP and AMP is rapid and reversible. AMP is slowly
converted into adenosine and then inosine and xanthine through
a purine degradation pathway. These nucleosides leak out of the
cell (and may have vasodilator effects through purinergic
receptors) and lead to a gradual depletion of adenine nucleotide
which may contribute to the reduced cardiac performance
(stunning) seen on reperfusion.
Another feature of ischaemia that is thought to contribute to
the damage seen during reperfusion is the production of reactive
oxygen species (ROS). There is a small increase in ROS
production immediately the heart becomes ischaemic which
remains stable for 20–25 min but then increases dramatically
[27]. This large increase is thought to play a major role in
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reperfusion as described below. However the source of the ROS
is unclear and might involve complex 1 and complex 3 of the
respiratory chain or perhaps more likely xanthine oxidase acting
on xanthine formed from the degradation of adenosine as noted
above [26,28–31]. The depletion of ATP combined with
elevated [Ca2+] and ROS leads to a gradual decline in cellular
integrity as degradative enzyzmes are activated and ATP-
dependent repair processes are unable to operate [1,3,26,32]. If
the tissue remains ischaemic for only short periods and the
mitochondria remain sufficiently intact to generate the ATP,
tissue damage is slight and can be repaired by ATP-dependent
processes upon reoxygenation. However, a critical point is
reached when recovery is not possible and reperfusion actually
causes further damage to the heart, causing extensive necrosis
with associated enzyme release [1,3].
3.2. Damage occurring during reperfusion
Reperfusion is associated with a burst of reactive oxygen
species (ROS) production [27], but here too the source of the
ROS is debated. Although some may be produced by xanthine
oxidase and NADPH oxidase, it is probable that most is formed
by complex 1 and complex 3 of the respiratory chain [26,28–
30]. When the respiratory chain is inhibited by lack of oxygen
and then re-exposed to oxygen, ubiquinone can become
partially reduced to ubisemiquinone. This can then react with
the oxygen to produce superoxide that is reduced to hydrogen
peroxide by superoxide dismutase. Hydrogen peroxide is
removed by glutathione peroxidase or catalase, but if ferrous
ions (or other transition metals such as copper) are present it will
form the highly reactive hydroxyl radical through the Fenton
reaction [28]. Mitochondrial proteins are especially susceptible
to ROS induced damage and this is reflected in the impaired
respiratory chain activity of mitochondria isolated from
ischaemic hearts (see [26,31]). Thus ROS have direct effects
on several respiratory chain components, most especially on
complex 1 but also on complex 3, and other iron sulphur
proteins such as aconitase. ROS can also cause thiol oxidation
and inhibition of the ATPase and adenine nucleotide translo-
case. In addition, ROS cause oxidation of glutathione that may
then form mixed disulphides with proteins. Such protein
modification is thought to have inhibitory effects on ion
pumps and therefore exacerbate the effects of ATP deprivation
on ionic homeostasis [33–35]. ROS also cause peroxidation of
the unsaturated fatty acid components of the phospholipids, and
especially cardiolipin of the inner mitochondrial membrane, and
this leads to further inhibition of respiratory chain activity
[36,37]. Furthermore, lipid peroxidation causes the release of
reactive aldehydes such as 4-hydroxynonenal that can modify
membrane proteins [38]. Overall, it is thought that the combined
effects of ROS and elevated [Ca2+] play a critical role in the
transition from reversible to irreversible reperfusion injury, and
that mitochondria are the major target of these agents. In
particular, they lead to the opening of the mitochondrial
permeability transition pore, that is now widely accepted to play
a critical role in reperfusion injury [1,3,10,26,39].4. The mitochondrial permeability transition pore (MPTP)
4.1. Properties of the MPTP
Under normal physiological conditions, the mitochondrial
inner membrane is impermeable to all but a few selected
metabolites and ions; this is essential to maintain the membrane
potential and pH gradient that together drive ATP synthesis
through oxidative phosphorylation. However, under conditions
of high matrix calcium, especially when this is accompanied by
oxidative stress, high phosphate and low adenine nucleotide
concentrations, a non-specific pore opens in the inner
mitochondrial membrane known as the mitochondrial perme-
ability transition pore (MPTP). The properties and regulation of
the MPTP are reviewed extensively elsewhere [3,40,41]. Once
open, this pore allows free passage of any molecule of b1.5 kDa
and so disrupts the permeability barrier of the inner membrane.
This has two major consequences. First, it allows unrestricted
proton movement across the inner membrane, causing oxidative
phosphorylation to be uncoupled. Not only does this prevent
ATP synthesis but it also enables the proton-translocating
ATPase to reverse direction and so actively hydrolyse ATP
rather than synthesise it. Under such conditions, intracellular
ATP concentrations rapidly decline, leading to the disruption of
ionic and metabolic homeostasis and activation of degradative
enzymes such as phospholipases, nucleases and proteases
[3,9,26]. Unless pore closure occurs, these changes will cause
irreversible damage to the cell resulting in necrotic death.
It should be noted that opening of just a single pore in one
mitochondrion is likely to cause its immediate depolarisation.
This will then activate further pore opening in the same
mitochondrion since MPTP opening of calcium loaded
mitochondria is activated by depolarisation [42]. Thus mito-
chondria are either fully open or closed, and it is the fully open
state that leads to the second consequence of MPTP opening;
the mitochondria swell extensively [43]. This occurs as all small
molecular weight solutes equilibrate across the inner membrane,
leaving the high concentration of matrix proteins to exert a
colloidal osmotic pressure that leads to the uptake of water and
matrix swelling. Although unfolding of the cristae allows the
matrix to expand without rupture of the inner membrane, the
outer membrane will break and lead to the release of proteins in
the intermembrane space such as cytochrome c and other
factors that play a critical role in apoptotic cell death [44,45].
4.2. The molecular identity of the MPTP
The molecular identity of the mitochondrial permeability
transition pore remains uncertain [40,41,46], but it is generally
accepted that an inner membrane component undergoes a
calcium-triggered change in conformation that is facilitated by
cyclophilin D (CyP-D), a peptidyl-prolyl cis-trans isomerase
[46,47]. The role of CyP-D was first suggested by the discovery
that cyclosporin A (CsA) acts as a potent inhibitor of pore
opening [48]. Further studies revealed that the potency of
different CsA analogues to inhibit pore opening correlates with
their ability to inhibit the peptidyl-prolyl cis-trans isomerase
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identified as CyP-D [51,52]. Extensive work from many
laboratories confirmed the critical role of CyP-D and this was
finally put beyond doubt by the demonstration that MPTP
opening in liver mitochondria from CyP-D knockout mice is
much less sensitive to calcium than normal mitochondria, and is
no longer inhibited by CsA [53–55].
The identity of the membrane component of the MPTP is
less certain. However, the most widely accepted view is that
the adenine nucleotide translocase (ANT) normally fulfils this
role and extensive circumstantial data supports this view (see
[9,56]). Thus opening of the MPTP is inhibited by adenine
nucleotides with a similar concentration dependence and
specificity as they exhibit when acting as substrates for the
ANT, and this inhibition is overcome by the specific inhibitor
of the ANT, carboxyatractyloside (CAT) that traps the ANT in
its “c” conformation. By contrast, another inhibitor of the ANT,
bongkrekic acid, that causes the carrier to take up the
alternative “m” conformation, inhibits pore opening [57]. The
ANT can also account for the sensitisation of the MPTP to
calcium by oxidative stress and the vicinal thiol reagent
phenylarsine oxide (PAO) [57]. Thus cysteine residues 160 and
260 of rat ANT2 can be cross-linked by oxidative stress or
PAO, with modification of Cys160 alone being sufficient to
prevent the inhibition of MPTP opening by adenine nucleo-
tides, so stimulating pore opening [58]. Further evidence for an
important role for the ANT is the ability of the ANT to bind to
CyP-D in a CsA-sensitive manner [58,59]. In addition, when
the purified ANT is reconstituted into proteoliposomes high
calcium concentrations can induce the formation of non-
specific channels [60] and this process is sensitised to [Ca2+]
by the addition of purified cyclophilin [61]. Nevertheless,
despite the strong evidence in favour of the ANT being the
critical membrane component of the MPTP, it is unlikely to be
essential. Thus in an elegant study, that has yet to be confirmed
by others, mitochondria from mouse livers in which ANT1 and
ANT2 had been knocked out were found to exhibit MPTP
opening that was inhibited by CsA [62]. However, pore
opening in the ANT-knockout mitochondria required much
higher calcium concentrations than did wild-type mitochon-
dria, and was no longer sensitive to adenine nucleotides
confirming that the ANT is at the very least playing a critical
regulatory role. One possibility is that the ANT is the normal
membrane component of the MPTP but that other less
abundant members of the mitochondrial carrier family can
fulfil this role in the absence of the ANT [63]. An alternative
possibility, proposed by Lemasters, is that unfolded membrane
proteins form the MPTP and that the ANT is the most abundant
of these [64].
Many other proteins have been proposed to be components
of the MPTP, including the peripheral benzenediazipine
receptor, creatine kinase and the voltage dependent anion
channel (VDAC) [3,40,41,65]. Of these perhaps the strongest
candidate is VDAC since an interaction between VDAC and the
ANT has been demonstrated and there is evidence that the
MPTP may be associated with contact sites between the inner
and outer mitochondrial membranes [3,40,65]. Furthermore,initial reports suggested that VDAC might be the locus for
inhibition by ubiquinone analogues [66]. However, the recent
demonstration that liver mitochondria from mice lacking
VDAC1 exhibit normal MPTP opening and inhibition by
ubiquinone analogues [67] make an essential role for VDAC1
unlikely. See note added in proof.
5. The MPTP opening plays a central role in reperfusion
injury
5.1. The MPTP opens during reperfusion but not ischaemia
We have developed a technique to demonstrate that the
MPTP is kept firmly closed in the heart under normal
physiological conditions, but opens upon reperfusion following
a period of ischaemia. This technique involves measuring the
extent of [3H]-2-deoxyglucose entrapment in mitochondria that
have undergone the permeability transition [68]. Others have
used fluorescence microscopy to measure MPTP opening in
isolated cardiac myocytes and have also confirmed that the pore
opens under conditions of simulated ischaemia and reperfusion
[69]. It might be expected that the pore would also open after
prolonged ischaemia and some have reported this to be the case
[70,71]. However, these studies relied on cytochrome c release
as a measure of MPTP opening, but it is known that this can
occur independently of the MPTP as a result of Bax
translocation to mitochondria during ischaemia [72]. By
contrast, our own direct measurements [68] and those of others
[73] do not support MPTP opening in ischaemia. Since the pore
has been shown to be powerfully inhibited by low pH (b7) [74]
and the time course of opening during reperfusion correlates
with the return of pH to normal [75], we have suggested that it is
the low pH accompanying ischaemia that prevents pore opening
despite the conditions of oxidative stress, low adenine
nucleotide and elevated phosphate and calcium [75]. Indeed,
as would be predicted, maintaining a low pH during the initial
phase of reperfusion is known to protect hearts from reperfusion
injury [76–78] and may play a role in the cardioprotective
effects of inhibitors of the Na+/H+ exchanger such as amelioride
and cariporide (see [3,79,80]). A similar mechanism has also
been implicated recently in the protection offered by post-
conditioning [81,82].
It has also been proposed that the rapid energisation of
mitochondria at reperfusion will lead to electrogenic calcium
uptake into themitochondria. Since the calcium has accumulated
in the cytosol during ischaemia, this might be expected to induce
mitochondrial calcium overload and henceMPTP opening [1,9].
However, measurements of mitochondrial [Ca2+] in isolated
cardiac myocytes imply that it is the mitochondrial [Ca2+] at the
end of ischaemia rather than during reperfusion that correlates
better with cell injury [83]. Another factor that will reinforce
MPTP opening at reperfusion is the surge of ROS production
that is known to occur [27,84] and this may well be the most
important factor in determining the outcome of reperfusion [73].
Indeed, there is increasing evidence that the extent of MPTP
opening is a critical factor in the transition from reversible to
irreversible reperfusion injury [1,3,9,65]. More accurately, it is
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with damage, since we have demonstrated that some mitochon-
dria in which the MPTP opens initially, subsequently undergo
pore closer as reperfusion continues [75,85]. It is possible that
myocytes in which the majority of mitochondria have undergone
such reversible MPTP opening will have swollen sufficiently to
release pro-apoptotic proteins such as cytochrome c and thus
initiate apoptosis as noted in Section 4.1. These myocytes are
likely to be at the periphery of the infarct where the ischaemic
insult was incomplete and thus would account for the ring of
apoptotic myocytes that have been observed to surround the
necrotic core of the infarct [5,6]. It should be noted that mice in
which CyP-D had been knocked out demonstrate normal
development and cells from them respond to a range of apoptotic
stimuli in the same manner as wild-type mice [54,55]. Thus
MPTP opening cannot the mechanism by which apoptosis is
mediated in the healthy animal, but this does not preclude
apoptosis being induced in this way under pathophysiological
situations such as those described above [46].
5.2. Inhibition of MPTP opening protects hearts from
reperfusion injury
If the opening of the MPTP is a critical event in reperfusion
injury then it would be predicted that inhibition of pore opening
should protect hearts from injury. Many studies have confirmed
that this is the case. Protection was first demonstrated with CsA
which, when added prior to global ischaemia, was shown to
improve haemodynamic function and ATP levels on reperfusion
and to decrease necrotic damage as reflected in intracellular
enzyme release [86]. Subsequent studies have shown that other
CsA analogues, and the alternative CyP-D inhibitor sanglifehrin
A (SfA) also provide protection under these conditions
[68,87,88] whilst mitochondria isolated from these hearts
showed less pore opening in response to a given calcium load
[88,89]. In addition, CsA and SfA can reduce the infarct size of
hearts in which a coronary artery is occluded and then re-opened
to mimic the treatment of a coronary thrombosis. In this model
of reperfusion injury, protection is observed even when the drug
is added only at reperfusion [90,91].
Less direct approaches to inhibit MPTP opening are also
effective at protecting the heart from reperfusion injury. Thus
free radical scavengers are well known to be protective and in
the case of one such agent, the anaesthetic propofol, we have
used the 2-deoxyglucose entrapment technique to confirm
inhibition of the MPTP directly [92]. In addition, we have
demonstrated that propofol provides protection from reperfu-
sion injury in a pig model of open heart surgery [93].
Inhibition of the sodium proton exchanger with cariporide is
also known to protect the heart from reperfusion injury [94]
and here too inhibition of MPTP opening correlates with this
protection [80]. This protection probably reflects less sodium
and hence calcium loading of the cardiac myocytes during
ischaemia, coupled with a lower pH during the initial phase of
reperfusion, both of which will reduce MPTP opening. The
most powerful agent for inhibiting MPTP opening and
protecting the heart is pyruvate [75,95]. The presence of10 mM pyruvate during ischaemia and reperfusion can almost
totally protect rat hearts from 30 min global ischaemia and this
is accompanied by greatly reduced MPTP opening followed by
total pore closure [75]. Pyruvate has three beneficial effects
that may contribute towards its inhibition of MPTP opening: it
is a free radical scavenger, it maintains a lower intracellular pH
during the early phase of reperfusion and it is an excellent fuel
for ATP synthesis that bypasses the ATP-requiring steps of
glycolysis [75,96].
5.3. Protection by preconditioning involves inhibition of MPTP
opening
In view of the critical role of the MPTP in reperfusion injury
and the proven ability of inhibitors of the MPTP to protect from
injury it might be predicted that ischaemic preconditioning (IP)
would inhibit pore opening. Both direct and indirect techniques
have been used to confirm this. Our own experiments have used
the 2-deoxyglucose entrapment technique to demonstrate that
less MPTP opening occurs at reperfusion in preconditioned
hearts and that as reperfusion continues the majority of
mitochondria that originally opened close again in the IP hearts
but not in control hearts [85]. Others have used confocal
microscopy to monitor mitochondrial membrane potential in an
isolated cardiac myocyte model of preconditioning and shown
that IP desensitises the mitochondria to pore opening induced
by oxidative stress [69,97]. Recent experiments performed with
two-photon microscopy in the perfused heart have confirmed
these data [98]. Yet other studies have investigated the
sensitivity of isolated mitochondria from control and IP hearts
to pore opening in response to added calcium [85,99,100]. Both
light scattering and mitochondrial calcium retention techniques
demonstrated that when mitochondria were isolated immedi-
ately after the preconditioning stimulus, those from IP hearts
were not any less sensitive to calcium-induced pore opening
than those from control hearts. Indeed, if anything they were
more sensitive [85,100]. When isolated at the end of ischaemia
or during the first few minutes of reperfusion mitochondria
were more sensitive to MPTP opening than those isolated
prior to ischaemia but at these time points mitochondria from
IP hearts were considerably less sensitive to calcium-activated
pore opening than those from control hearts [99–101]. These
data clearly show that the IP protocol alone is not having a
direct effect on the MPTP but suggest that IP inhibits a
process occurring during ischaemia and reperfusion that is
responsible for sensitising the MPTP to calcium. This is an
important fact to bear in mind when evaluating the extensive
literature surrounding the mechanisms by which precondition-
ing exerts its protective effects as will be discussed further
below (Section 6).
Temperature preconditioning, where hearts are exposed to
three brief hypothermic (26 °C) episodes prior to normothermic
ischaemia is also thought to protect through inhibition of the
MPTP [101] as is post-conditioning [102]. Thus, mitochondria
isolated from such hearts during reperfusion are less sensitive to
MPTP than those isolated from control hearts with temperature
preconditioning being even more protective than IP [101].
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of the MPTP
There is a plethora of data implicating many different
signalling pathways in preconditioning and the relevant role of
each remains hotly debated (see [16,30,103–107]). Many of
these studies have utilised pharmacological agonists and
antagonists of components of the different signalling kinase
cascades and their potential targets. The complex interactions
that exist between different signalling pathways makes inter-
pretation of these data complicated and this is made worse by
the questionable specificity of some of the pharmacological
interventions. The reader is referred elsewhere for a detailed
consideration of the many potential pathways that have been
proposed [30,103–107]. Here we will only provide a brief
overview before focussing on how they may exert their effects
on the mitochondria.
6.1. The role of protein kinase C
There is extensive evidence that protein kinase C (PKC)
plays a central role in preconditioning since inhibition of PKC
has been shown to block the protection afforded by IP and
pharmacological activators of PKC are cardioprotective (see
[105]). There remains some controversy over which of the many
PKC isoforms may be involved in IP, whether they translocate
to the particulate fraction and how they exert their effects [103].
Nevertheless, there is a large body of evidence to implicate
PKCε as an important player in IP [105]. Thus hearts from
PKCε knockout mice do not exhibit IP [108] whereas transgenic
mice with cardiac-specific over-expression of PKCε or expres-
sion of an activator of PKCε are protected from reperfusion
injury [109–111]. Some studies have reported PKCε transloca-
tion to the particulate fraction, including mitochondria [112–
114] and have suggested a direct inhibition of the MPTP by
PKCε involving phosphorylation of components of the MPTP
such as the voltage dependent anion channel (VDAC) [113–
115]. However, in our own studies we were unable to detect
PKCε translocation to the mitochondria of IP hearts (Fig. 1A)
whilst others have observed that PKC translocation to the
particulate fraction following IP is transient and lost during
progressive brief cycles of ischaemia and reperfusion [116].
Although a role for PKCε in IP seems established, the
mechanism(s) by which it exerts its effects are less clear as will
become apparent below (see sections 7–10). It is also uncertain
how ischaemic preconditioning activates PKCε, although
several pathways may be involved. Factors released during
the brief ischaemic periods such as adenosine, bradykinin,
noradrenaline and opioids may bind to their G protein-coupled
receptors to stimulate phospholipase C, producing diacylgly-
cerol that activates PKC. Indeed, all of these factors can
pharmacologically precondition the heart [104]. Accumulating
evidence supports a role for the modest increase in ROS that
occurs during IP protocol in the activation of PKC [27,117,118].
Thus ROS are known to activate PKC in the isolated heart
[118–120] and IP can be prevented if free radical scavengers are
present during the preconditioning phase [100,101,118,121]Oxidation of critical cysteine residues on PKC isoforms is
known to cause their activation [35,122] and thus provides a
mechanism by which ROS could activate PKC.
6.2. The role of nitric oxide and cyclic GMP dependent protein
kinase
Data from several laboratories have implicated activation of
cyclic GMP dependent protein kinase (PKG), perhaps by nitric
oxide, in the signalling pathway for IP. Thus it has been reported
that nitric oxide donors and PKG activators can induce
preconditioning whilst NO scavengers and PKG inhibitors
prevent preconditioning [106,123,124]. Pharmacological stu-
dies from Garlid's laboratory have led them to conclude that
PGK and PKCε work in concert to induce IP through an effect
on the putative mitochondrial ATP-dependent potassium
channel (mitoKATP — see Section 9 below). They propose
that cGMP activates PKG localized at the cytosolic surface of
the mitochondrial outer membrane and that this phosphorylates
some target protein which in turn can somehow activate PKCε
residing in the intermembrane space of mitochondria. This
PKCε then would phosphorylate the mitoKATP channel to
mediate preconditioning [123]. In a subsequent paper they
proposed that activation of the mitoKATP channel increased
ROS formation and that this ROS activated a second pool of
PKCε that inhibited the MPTP [125]. Our own data do not
support this (see Sections 7). It should be noted that an
alternative or additional mechanism has been proposed by
which nitric oxide may protect the heart when present during the
initial stages of reperfusion (see [128]). Cytochrome oxidase is
competitively inhibited by nitric oxide and this would lead to an
inhibition of respiration and hence a reduction in the
mitochondrial membrane potential. It is suggested that one
consequence of this would be less mitochondrial calcium
accumulation and hence less MPTP opening. However, another
consequence of a lower mitochondrial membrane potential
would be impaired ATP production which would not be
predicted for hearts showing improved recovery. Similar
arguments have been made for the proposed depolarisation
caused by mitochondrial KATP channel opening and these will
be considered in more detail in Section 10.2.
6.3. The role of pro-survival kinases
Several laboratories have presented evidence to implicate
activation of pro-survival kinases such as Akt (protein kinase B)
in preconditioning [107,126]. It is proposed that tyrosine
kinases are activated during IP through some ill-defined
interaction with G-protein coupled receptors such as the
adenosine and bradykinin receptors and that this causes
activation of phosphatidyl inositol 3 phosphate kinase (PI-3-
kinase). The resulting phosphatidylinositol 3,4-bisphosphate
then activates phosphoinositide-dependent kinase 1 (PDK1)
that in turn phosphorylates and activates Akt. However, it is also
possible that activation of tyrosine kinases or inhibition of
tyrosine phosphatases and the phosphatidyl inositol 3,4,5,-
trisphosphate phosphatase PTEN (Phosphatase and TENsin
Fig. 1. Preconditioning is not accompanied by translocation of protein kinases to the mitochondria. Isolated rat hearts were preconditioned using two cycles of 5 min
ischaemia interspersed with 5 min reperfusion as described previously [72] or treated for 10 min with 50 μM diazoxide or 200 nM phorbol-12-myristate-13-acetate
(Phorbol ester). Five minutes after the second brief ischemic period or at the equivalent time for control and drug-treated hearts, mitochondria rapidly isolated in the
presence of buffer containing proteases and phosphatase inhibitors as described in [89] where further details of the Methodology are given. In Panel A samples of the
post-mitochondrial supernatant (Cyt) and the mitochondria before (Crd) and after (Mit) removal of contaminating membranes by Percoll density gradient
centrifugation were separated by SDS-PAGE andWestern blotting performed using antibodies against PKCα, PKCε, MCT1 (as a sarcolemmal marker) and ANT (as a
mitochondrial marker). In Panel B similar experiments were performed but in this case crude samples of crude homogenate (after clarification by centrifugation at
2000×g for 5 min) were included (Hom) as were samples of the membrane fraction (Slm—primarily sarcolemma) removed by Percoll density gradient centrifugation.
Western blotting was performed using antibodies against total and phosphorylated forms of AMPK, GSK3β and Akt, as well as MCT1, ANT and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as markers for sarcolemma, mitochondria and cytosol. Data shown are previously unpublished data of the authors.
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preconditioning stimulus [107,127]. In support of this mechan-
ism it has been demonstrated that phosphorylation of Akt is
enhanced by IP, especially during reperfusion, and that
pharmacological inhibitors of either Akt or PI-3-kinase prevent
preconditioning [126,128–130]. It has further been proposed
that following phosphorylation, activated Akt phosphorylates
endothelial nitric oxide synthase to produces NO that acts via
PKG as noted above [106,107].
Sollott et al. [97] have suggested that all these kinases may
converge to phosphorylate and inhibit glycogen synthase kinase
3β (GSK3β) that they report translocates to the mitochondria.
Inhibition of GSK3β by Akt-induced phosphorylation would
then mediate protection. Although it is known that GSK3β is
pro-apoptotic and that its phosphorylation inhibits its activity
and stimulates cell survival [131], the mechanism of any
mitochondrial effects remain to be elucidated. However, it may
be significant that GSK3β has been reported to phosphorylate
VDAC, and that this phosphorylation is associated with a
sensitisation to cytotoxic drugs that stimulate pore opening
[132]. VDAC was widely regarded as an integral component of
the MPTP, but recent data showing that mitochondria from the
VDAC1 knockout mouse have a normal MPTP cast doubt on
this [53]. See note added in proof.
6.4. The role of AMP-activated protein kinase
Yet another protein kinase, AMP-activated protein kinase
(AMPK), is activated by a large variety of cellular stresses that
deplete ATP and increase AMP, including glucose deprivation,
hypoxia, ischaemia, oxidative stress and hyperosmotic stress
[133]. It could be argued that the many pharmacologicalagents known to induce preconditioning, from KATP channel
openers, to uncouplers and respiratory chain inhibitors (see
Section 10), might all represent insults to the heart that
increase AMP and so activate AMPK as the focus of a
common signalling mechanism to protect the heart [133].
Indeed, transgenic mice expressing a kinase dead form of
AMPK in the heart have been shown to exhibit greater
myocardial necrosis and apoptosis after ischaemia/reperfusion
[134] and cannot be preconditioned [135]. Furthermore,
Nishino et al. [136] have shown that PKC inhibitors abolished
AMPK activation by ischaemic episodes in the myocardium,
suggesting that AMPK might be activated by IP in a PKC-
dependent manner. However, our own data fail to show any
abrogation of the IP-induced protection by the inhibitor of
AMPK, compound C, under conditions where the inhibitor of
PKC, chelerythrine, did overcome the protection [101].
Taken together, all these data suggest that several signalling
pathways may interact or act in parallel to induce IP, but the
ultimate target of their action remains unclear. Since IP involves
inhibition of the MPTP the signalling pathway must ultimately
inhibit MPTP opening, but this could be achieved either by
direct phosphorylation of a component of the MPTP or
indirectly by influencing factors that enhance pore opening
such as by reducing oxidative stress or calcium overload.
7. Mechanism of inhibition of the MPTP by IP
7.1. Is there evidence for regulation by phosphorylation?
As noted above, there are several reports that protein kinases
may migrate to the mitochondria in response to IP suggesting
that phosphorylation of a component of the MPTP may be
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MPTP of isolated heart mitochondria was inhibited following
incubation for 15 min with purified PKCε plus phorbol ester
[115]. However, such experiments are hard to interpret since
incubating isolated mitochondria in vitro can change the
sensitivity of MPTP opening to calcium, especially if ATP is
added since this is an inhibitor of MPTP opening in its own right
[3,40]. Similar criticisms could be levelled against experiments
in which incubation of isolated rat liver mitochondria with a
cGMP analogue in the presence of a cytosolic extract and ATP
caused inhibition of the calcium-induced mitochondrial perme-
ability transition [137], although here reversal of the effect by
the PKG inhibitor KT5823 makes the data more convincing.
However, no data are available to show changes in phosphor-
ylation of any mitochondrial protein following IP that might
account for inhibition of the MPTP. Furthermore, when we and
others measured MPTP opening in mitochondria isolated
immediately after the preconditioning stimulus we observed
no reduction in sensitivity to calcium as might have been
predicted if a component of the MPTP had been phosphorylated
[85,100]. Indeed, it is unclear how activated cytosolic protein
kinases could cross the outer membrane to phosphorylate and
inhibit components of the MPTP, let alone cross the inner
membrane into the matrix. Although there are reports to suggest
that this occurs [97,113,114], our own attempts to demonstrate
the translocation of PKCε or GSK3β to mitochondria have
consistently failed as illustrated in Fig. 1. A key aspect of our
experiments was the use of Percoll gradient centrifugation to
remove plasma membrane contamination which we have shown
is significant in less pure mitochondrial fractions. This was
demonstrated by the presence of monocarboxylate transporter 1
(MCT1) in the crude but not the purified mitochondria.
Our inability to detect protein kinase translocation into the
mitochondrial matrix is entirely consistent with extensive work
from this laboratory more than 20 years ago in which high
specific activity 32P labelling was used to investigate the
phosphorylation of mitochondrial matrix proteins. Such studies
demonstrated the presence of two proteins within the mitochon-
drial matrix that could be phosphorylated in Percoll-purified
mitochondria from both heart and liver. These were pyruvate
dehydrogenase (PDH) and branched chain 2-oxoacid dehydro-
genase (BCDH) [138]. This was true whether the mitochondria
were from control or glucagon-treated (raised cyclic AMP) rats
[139], yet mitochondria from glucagon-treated rats were found
to exhibit enhanced calcium retention characteristic of reduced
sensitivity of the MPTP to calcium-induced opening [140,141].
Although these data do not support a role for protein kinases
within the mitochondrial matrix in the inhibition of the MPTP
following preconditioning, they do not exclude the possibility
of regulation by phosphorylation of proteins exposed to
cytosolic kinases, such as those in the outer mitochondrial
membrane or bound to it using scaffolding proteins [142,143].
Indeed, work from this laboratory many years ago demonstrated
that when mitochondria were isolated from hepatocytes
incubated with high specific activity 32P, or isolated mitochon-
dria were incubated with γ-[32P]-ATP, additional phosphory-
lated proteins were observed. Two of these proteins, both 30–35 kDa, demonstrated an increase in phosphorylation with
glucagon treatment [139,144]. However, a weakness of the 32P
labelling technique is that it will not detected proteins whose
phosphorylation turnover is small and this may account for the
larger number of phosphorylated proteins within mitochondria
detected using a phosphoprotein-specific dye [145]. Never-
theless, a lack of turnover might suggest that such a
phosphorylation does not play an important role in signalling.
There have been an increasing number or reports in which
proteomic and immunodetection methods have been used to
detect a variety of other kinases associatedwith themitochondria
[142,146]. However, the extent to which these represent real
mitochondrial kinases rather than non-specific mitochondrial
contamination of the mitochondrial fraction is hard to assess. We
have recently used a proteomics approach to identify any
mitochondrial proteins whose phosphorylation might be altered
by preconditioning. Mitochondria were isolated from control
and IP hearts immediately after the preconditioning stimulus as
well as the end of ischaemia and after three min reperfusion and
phosphor-proteins detected using 2-D gel electrophoresis and
staining with ProQ Diamond phospho-protein fluorescent dye.
Although a significant number of phospho-proteins were
detected in addition to the predominant spots representing
PDH and BCDH, no consistent changes were detected in any of
these in response to IP (unpublished data of S.J. Clarke, I.
Khaliulin, Kate Heesom and A.P. Halestrap). Typical data are
shown in Fig. 2. Overall, our data do not support a role for
mitochondrial protein phosphorylation in mediating the inhibi-
tion of MPTP opening by IP. Rather, our data suggests that the
inhibition of the MPTP by preconditioning may be secondary to
either diminished ROS production or calcium overload as
described below.
7.2. Effects of IP on ROS production and calcium loading
during ischaemia and reperfusion as potential mediators of
MPTP inhibition
As noted above, opening of the MPTP is triggered by
calcium overload especially when this is accompanied by
oxidative stress and these two parameters appear critical
determinants of the recovery of isolated heart cells from
simulated ischaemia. Indeed, the extent of recovery has been
reported to correlate inversely with mitochondrial matrix
calcium concentrations at the end of ischaemia [83,147] and
to be triggered by the rise in ROS during reperfusion [73]. It is
well established that preconditioning reduces ROS production
both at the end of ischaemia and during reperfusion
[27,84,148,149] and decreases mitochondrial calcium overload
[150–153]. Thus it is quite possible to account for the IP-
mediated inhibition of MPTP opening at reperfusion merely
through these indirect effects without having to invoke
phosphorylation of any mitochondrial protein.
Our own data are entirely consistent with this mechanism.
Opening of the MPTP in mitochondria isolated immediately
following the preconditioning stimulus showed the same
sensitivity to calcium as in control mitochondria [85,100].
Mitochondria isolated at the end of ischaemia, or during
Fig. 2. Preconditioning is not accompanied by phosphorylation of integral mitochondrial proteins. Density gradient purified mitochondria were isolated from control
and preconditioned rat hearts 5 min after the preconditioning protocol as described in Fig. 1. Mitochondrial proteins were separated by 2D electrophoresis in the
Proteomics Facility of the University of Bristol and gels stained with ProQDiamond to reveal phosphorylated proteins (red) followed by sypro-Ruby to stain all
proteins (green). The fluorescent images were scanned after each staining procedure and the images overlayed. The predominant phosphoprotein at about 50 kDa and
pI 6.5 were shown to be multiply phosphorylated forms of pyruvate dehydrogenase and branch-chain keto acid dehydrogenase that are known to be the dominant
phosphoproteins in heart mitochondria [138].
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opening than those isolated prior to ischaemia. However, at
these times the mitochondria from preconditioned hearts were
less sensitive to MPTP opening than were mitochondria
isolated from control hearts at the same time [99–101]. This
difference in sensitivity to calcium correlated with the
exposure of the mitochondria to oxidative stress as reflected
in the carbonylation of mitochondrial proteins [100,101], a
surrogate marker for oxidative stress [154]. These data
confirm that the oxidative stress mitochondria experience at
the end of ischaemia and during reperfusion is significantly
attenuated in preconditioned hearts. As such they provide
strong evidence in favour of IP exerting its primary effect on
the reduction of ROS levels during ischaemia and reperfusion
with the secondary consequence that MPTP opening is
diminished. If this is the case, the key signalling pathways
in preconditioning will be those that mediate the decrease in
ROS levels at the end of ischaemia and during reperfusion.
This could be the result of decreased ROS production or of
improved ROS removal, but the ability of preconditioning to
protect against oxidative stress mediated by exogenous
hydrogen peroxide [155,156] argues in favour of the latter.
However, an additional effect of IP to reduce ROS production
cannot be ruled out.
8. The role of mitochondrial potassium channels
Plasma membrane ATP-dependent potassium channels
(KATP) are strongly expressed in the heart and have long been
associated with cardioprotection [12,157]. It was originally
proposed that opening of the plasma membrane KATP channel
might hyperpolarize the cell leading to a shorter action potential
duration (APD) and hence less calcium entry during ischaemia
which would protect the hearts from calcium overload. In
support of this, mouse hearts whose KATP channel Kir 6.2 hadbeen knocked out exhibited greater calcium overload and
ischaemia/reperfusion injury than control hearts [146]. A role
for the sarcolemmal KATP channels in the protective mechanism
exerted by preconditioning was first suggested by the observa-
tion that KATP channel blockers such as glibencamide prevent
preconditioning (see [12,157]). Further support came from the
demonstration that hearts from the Kir 6.2 knockout mice were
insensitive to either ischaemic or pharmacological precondi-
tioning [158–160]. However, despite this convincing evidence
in favour of a role for the sarcolemmal KATP channel in
preconditioning, other data argue against such a role. In
particular conditions were found in which cardioprotection
could be observed in the absence of APD shortening whilst a
range of KATP channel openers were reported to show a poor
correlation between their effect on APD and their protective
effects (see [11,12,161–163]). These data led to a change of
emphasis, away from the sarlcolemmal KATP channel towards a
similar KATP channel proposed to reside in the mitochondrial
inner membrane.
8.1. The identity of mitochondrial K+ channels and their
physiological roles
The presence of an electrogenic mechanism for K+ entry into
mitochondria (K+ channel) together with a K+/H+ antiporter to
pump K+ out again has been known for more than 30 years, and
their relative activities are thought to play a key role in the
regulation of matrix volume (see [43,164]). What is less clear is
the identity of these channels and transporters since none have
been purified sufficiently to allow sequencing. Nor has genomic
analysis revealed any plasma membrane K+ channel isoform or
spliced variant with a mitochondrial targeting sequence [12].
Rather the presence and properties of the K+ channels and
transporters have been surmised from their functional char-
acterisation (see [165,166]).
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K+ channels
In isolated mitochondria, potassium ion movements can be
measured directly using isotopes or K+-sensitive fluorescent
dyes, or indirectly by determining matrix volume changes (see
[167–171]). For mitoplasts patch clamping has been employed
[172–174] whilst studies have been performed on proteolipo-
somes containing reconstituted inner mitochondrial membrane
proteins using electrophysiological measurement of single
channel current or fluorescent techniques to measure net K+
transport [168,175–179]. A major concern with the patch
clamping and reconstitution techniques is the possibility that
any channels detected in the mitochondrial membranes may
actually represent a small number of K+ channels present in
contaminating sarcolemmal membranes. It is known that most
preparations of isolated mitochondria are extensively contami-
nated with plasma membranes unless further purified by density
gradient centrifugation, and even then it is difficult to achieve
complete removal of contaminating membranes [180,181].
However, in the majority of published work no data were
presented to discount such contamination. Thus it is important
to confirm that the activity of any channels identified by such
techniques can be demonstrated in mitochondria, and this can
be achieved by measurements of mitochondrial matrix volume.
It is widely agreed that the matrix volume is regulated by the
relative activity of the K+ channels mediating membrane
potential driven potassium entry into mitochondria, and the
K+/H+ antiporter catalysing proton-linked K+ extrusion activity
[43,164,165,182]. Thus activation or inhibition of any K+
channel should lead to an increase or decrease in matrix volume
respectively. This can be measured either directly, using an
isotopic technique based around the permeability of 3H2O into
the matrix and the exclusion of [14C]-sucrose, or by light
scattering (see [165,182]). The latter provides a very sensitive
real-time measurement of matrix volume since as the mitochon-
dria swell, their refractive index decreases and they scatter less
light. Awavelength of 520 nm is frequently employed since this
represents the isosbestic wavelength at which changes in the
redox state of the mitochondrial cytochromes cause no change
in absorbance [182]. However, mitochondria can exhibit light-
scattering changes that are independent of changes in matrix
volume, reflecting rather a change in morphology or shape. It
has been known for many years that such morphological
changes, often referred to in terms of orthodox and condensed
conformations of mitochondria, can be induced by ligands of
the adenine nucleotide translocase (ANT) that switch the carrier
from the “c” to the “m” conformation [44,49,170,183,184].
Thus externally added ATP, ADP or bongkrekic acid induce the
“m” conformation of the ANT and cause a contraction of the
mitochondria detected as an increase in light scattering whilst
carboxyatractyloside, that induces the “c” conformation, exerts
the opposite effect. Yet these light scattering responses all occur
without changes in matrix volume measured isotopically
[44,49,170,171].
Garlid and Paucek dismiss these data, stating that “this claim
cannot be supported by any theoretical argument”, but the basison which they make this assertion is unclear. First, the claim is
backed up by experimental data from two different laboratories
[44,49,170,171]. Second, the curvature of the mitochondria
relative to the wavelength of light determines its refractive
index and hence light scattering properties [182]. Thus a shape
change without a change in volume (e.g. from a sphere to a
cylinder) will affect the light scattering signal. Since the ANT
represents some 25% or more of the inner membrane protein in
heart mitochondria [185], it is not surprising that when it
switches its conformation it can cause a change in mitochondrial
morphology and hence light scattering. Third, Garlid and
Paucek argue that changes in light scattering induced by
adenine nucleotides must reflect mitochondrial volume changes
because they did not observe them in potassium free medium.
They go on to say “If Das et al. had carried out these simple
control experiments they would have avoided spurious claims
about conformational changes”. However, we [170] and
Brustovetsky et al. [171] have reported other controls that
confirm that the adenine nucleotide-induced light scattering
changes do not reflect changes in matrix volume. Thus
additions of very low concentrations of valinomycin (0.4 to 1
pmol per mg mitochondrial protein) induced changes in matrix
volume of 10–25% that were readily detectable using radio-
isotopes, yet the magnitude of the light scattering changes were
similar to those induced by ADP or ATP for which no detectable
changes in matrix volume were detected (see Fig. 3 and
[170,171]). We have also performed experiments in potassium
free media as suggested by Garlid and Paucek, which we report
in Fig. 3. These data clearly show that such adenine nucleotide
induced changes in light scattering do occur in potassium free
medium and similar results were obtained by Brustovetsky et al.
[171]. We suggest that experiments directed towards investigat-
ing the activity of K+ channels in intact mitochondria that rely
entirely upon light scattering changes for measurement of
matrix volume should be treated with caution. Parallel isotopic
measurements of matrix volume provide an essential confirma-
tion that such light scattering changes do reflect changes in
volume rather than morphology.
8.3. Evidence for the mitochondrial KATP channel
Some 20 years ago we showed that adenine nucleotides
could inhibit electrogenic mitochondrial K+ entry into mito-
chondria and that this was probably mediated by their binding to
the ANT [49,186,187], in agreement with earlier proposals
[188]. More recent data obtained with brain mitochondria have
confirmed this proposal [171]. However, the existence of a
mitochondrial KATP channel similar to that found in the plasma
membrane was first formally proposed as a result of data
obtained using patch clamping of giant fused mitoplasts from
liver mitochondria [172] and light scattering experiments in
isolated mitochondria [189]. Subsequently this channel has
been studied extensively in several other laboratories (see
[165,166]). Experiments using reconstituted proteoliposomes
reported the characterisation of these channels with respect to
the specificity for nucleotide inhibition and the activity of a
range of pharmacological channel openers and blockers. In
Fig. 3. No evidence for mitochondrial matrix volume changes induced by openers and blockers of the putative mitochondrial KATP channel. Data of Panels A and B are
modified from [160] where further details may be found. Panel A show the light scattering changes of energised rat heart mitochondria induced by the addition where
indicated of 0.2 mM ATP, 5 μM carboxyatractyloside (CAT), 0.2 and 0.5 nM valinomycin (Val) and 50 μM 5HD, diazoxide or glibencamide. Where ATP or 5HD are
present from the start this is indicated on the left of the trace. Panel B shows the corresponding matrix volume changes induced by valinomycin or ATP as measured
using 3H2O and [
14C]-sucrose. Panel C represents previously unpublished data that compares light scattering changes of energised mitochondria that are induced by
ATP and CAT in KCl and tetraethylammonium (TEA) media. The latter was used by Garlid and colleagues (see [165]) as a potassium free medium to establish whether
these changes are independent of K+ movements across the inner mitochondrial membrane.
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plasma membrane KATP channel lending support to the
possibility that it is actually these channels present in
contaminating plasma membranes that are being characterised,
rather than true mitochondrial channels (see Section 8.2).
However, there are a number of differences in the reported
properties of mitochondrial and sarcolemmal KATP channels
that argue against this. For example, mitochondrial KATP
channels have been reported to require the presence of Mg2+
for ATP to inhibit them, which is not true of the plasma
membrane KATP channel. In addition, ADP acts like ATP to
inhibit the mitochondrial channel but opens the sarcolemmal
channel, whilst GTP has been reported to open the mitochon-
drial KATP channel but not the plasma membrane one [176,177].
Furthermore, their measured conductances were reported to be
distinct [165] and different dose response curves for a range of
pharmacological openers and blockers have been described
[165,168,190]. This is especially true of the KATP channel
opener diazoxide that has been reported to show a sensitivity
towards the mitochondrial KATP channel at least three orders of
magnitude greater than for the sarcolemmal KATP channel
whilst 5-hydroxydecanoate (5HD) blocks the mitochondrial
channel whilst having little effect on the sarcolemmal one[167,168]. However, there are other data claiming that diaz-
oxide will open and 5HD block plasma membrane KATP
channels at the concentrations frequently used to modulate
mitochondrial KATP channels when investigating their possible
role in cardioprotection [191–194].
Although no molecular identity has been ascribed to the
mitochondrial KATP channel at the genomic level, similarities
with the components of the plasma membrane KATP channels
have been proposed. These contain one of two channel
components, Kir6.1 (48 kDa) or Kir6.2 (44 kDa) and the
sulphohylurea receptors, SUR1 (177 kDa) or SUR 2 (174 kDa)
[12]. Two studies reported that antibodies against Kir6.1 and
Kir6.2 detected proteins of the right size (about 45 kDa) in heart
mitochondria, but no rigorous steps were taken to remove
sarcolemmal contamination [166,195]. In heart mitochondria
SUR2 antibodies detected a protein of about 25 kDa in one
study [195] but no protein in the other study [166], whilst a
protein of about 28 kDa was labelled by [125I]-glibencamide
[196]. Overall, the available data provide no strong evidence
for the presence of a KATP channel in mitochondria that is
closely related to the well-characterised plasma membrane
KATP channel. Garlid's laboratory found proteins of 55 kDa
and 63 kDa in a partially purified preparation from brain
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activity when reconstituted into proteoliposomes. The 63-kDa
protein showed labelling by a fluorescent glibencamide deri-
vative [197] leading them to surmise that the 55-kDa protein
represented the channel forming component, but no sequence
data were presented to identify either component. Furthermore,
because only Coomassie blue staining of proteins was used, it
was not established that there were not other minor components
present in the partially purified preparation used and the high
activity of channel proteins would only require a small
contamination to produce significant channel activity. Indeed,
it should be noted that mitochondrial preparations used in this
study were unpurified on density gradient and therefore
unavoidably would have contained significant contamination
by fragments of plasma membrane and thus plasmalemmal
KATP channels. This might explain why Garlid and co-workers
found 6 to 7 times larger amounts of KATP channel in their
preparations of isolated brain mitochondria than reported in
liver or heart mitochondria.
In view of the problems associated with the reconstitution
and patch-clamping studies discussed above, and the absence of
a molecular identity for the mitochondrial KATP channel, the
best evidence for the activity of mitochondrial KATP channels
should come from the measurement of changes in matrix
volume of isolated mitochondria in response to channel openers
and blockers. In this context, Garlid's laboratory has performed
extensive experiments using light scattering to detect matrix
volume changes in response to adenine nucleotides and a
variety of KATP channel openers and blockers. However, as
noted above (Section 8.2), we believe that without direct
measurements of matrix volume these data must be treated with
caution. Thus, although data from both this laboratory and that
of Brustovetsky confirmed effects of adenine nucleotides on
light scattering that are consistent with the presence of a KATP
channel, neither laboratory was able to detect volume changes
isotopically despite demonstrating with valinomycin that the
technique was quite sensitive enough to do so should they occur
[170,171]. Furthermore, neither we nor Brustovetsky et al. were
able to detect any significant changes in light scattering with a
variety of KATP channel openers (diazoxide, nicorandil,
cromakalim, pinacidil, minoxidil) or blockers (5HD and
glibencamide) [170,171]. Our own data have led us to conclude
that if mitochondrial KATP channels exist, there is no strong
evidence for them being active in isolated mitochondria.
However, this does not preclude such channels being active
within the intact cell, since we might be losing a factor during
mitochondrial isolation that is required for their activity. We
will consider if there is any evidence for this in the context of
studies investigating the role of mitochondrial KATP channels
in preconditioning (Section 9.1).
8.4. Evidence for a mitochondrial calcium-activated
K+ channel
Our own laboratory was the first to suggest that calcium
might regulate potassium entry into mitochondria and hence
matrix volume (see [182,198]). We demonstrated that K+ entryinto liver mitochondria was stimulated by hormones that
activated gluconeogenesis, such as glucagon, adrenaline and
vasopressin, and that this led to an increase in matrix volume
that was important for the stimulation of mitochondrial
respiration and ATP production [182,198]. The mechanism
was shown to involve a rise in matrix calcium that inhibits
pyrophosphatase leading to a rise in matrix pyroposphate (PPi).
Indeed, elevating matrix [PPi] independently of Ca2+, for
example by provision of butyrate, also caused modest
mitochondrial swelling [186]. Since PPi was known to bind to
the ANT [199–201] and adenine nucleotide depletion had been
reported to increase mitochondrial K+ uptake [202,203], we
proposed that the ANT could act as a potassium channel when
ATP was displaced by PPi [186]. In support of this we
confirmed earlier data [188] that the permeability of the inner
membrane to K+ was increased in the presence of atractyloside
which inhibits the ANT by trapping it in the “c” conformation
[186]. This mechanism has recently received support from
studies on brain mitochondria where it was shown that
carboxyatractyloside could enhance potassium loss from de-
energised mitochondria [171].
Our own data were unable to demonstrate calcium mediated
increase in either matrix [PPi] or volume in isolated rat heart
mitochondria [180,204]. However, data from O'Rourke's
laboratory [174] have suggested the presence of a calcium-
activated potassium channel (KCa) in these mitochondria. These
workers employed patch-clamped mitoplasts to characterise
mitochondrial KCa channels that, like the sarcolemmal KCa
channels were blocked with charybdotoxin. Furthermore,
antibodies against sarcolemmal KCa channels detected immu-
noreactive proteins in the mitoplasts. One problem with these
data is that, as noted above, it is well established that isolated
mitochondria are contaminated with plasma membrane and thus
it is possible that the immunological and patch clamping data
were actually detecting the sarcolemmal KCa.
9. Is there good evidence for mitochondrial K+ channels
being involved in the protective mechanism of
preconditioning?
9.1. The use of pharmacological agents is hampered by lack of
specificity
There are numerous studies reporting protection of hearts
from ischaemia reperfusion injury by drugs that are claimed to
be specific openers of the mitochondrial putative mitochondrial
KATP channel, most notably diazoxide, and the prevention of
this effect by supposed specific blockers of the channel, in
particular 5HD (see [11,12,161–163]). However, when haemo-
dynamic performance of the heart is used to assess recovery
after ischaemia/reperfusion, the effect of 5HD to reverse the
protective effects of diazoxide is not universally observed
[205,206]. O'Rourke et al. have suggested a role for the putative
mitochondrial KCa channels in preconditioning, in addition to
mitochondrial KATP channels. This proposal was based on the
observation that the KCa agonist NS-1619 decreased the infarct
size upon reperfusion after ischaemia, and this was blocked by
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(Section 8.3), a major problem associated with such studies is the
assumption that the pharmacological agents used are only
exerting their effects on the mitochondrial KATP or KCa channels.
In the absence of independent verification of this, the
conclusions drawn must be treated with caution. This is
especially so in the light of increasing evidence that these
agents have other non-specific effects onmitochondria including
inhibition of the respiratory chain and uncoupling as is discussed
below.
Diazoxide has been shown by many laboratories including
our own to inhibit succinate dehydrogenase at concentrations
usually used (50 μM) to open the mitochondrial KATP channel
[169,206–209]. Because inhibiting succinate dehydrogenase
will also block the citric acid cycle in an intact cell, this may
well perturb cellular energy metabolism leading to mild
depolarisation of the mitochondria and flavoprotein oxidation.
It has also been reported that both diazoxide and pinacidil can
uncouple mitochondria although the concentrations (N50 μM)
required to produce a significant depolarisation are at the high
end of the spectrum used in in vivo studies [210,211].
Interestingly these effects appear to require an interaction with
the ANT [210] and modelling studies based around the
published structure of the ANT have shown potential drug
binding sites on this membrane protein [212].
The specificity of mitochondrial KATP blockers is also
doubtful, especially for the most commonly used 5 HD which is
a substituted fatty acid and has the potential to be metabolised.
Indeed, our own work from and that of others has confirmed
that 5 HD can be activated to its CoA derivative and then further
metabolised through the β-oxidation pathway [206,209,213].
As such it can act as a poor respiratory substrate. In addition, the
slow kinetics of 3,5-dihydroxydecanoyl-CoA oxidation by l-3-
hydroxyacyl-CoA dehydrogenase, the penultimate step of the
pathway, can produce a bottleneck that can inhibit normal fatty
acid oxidation [206,214]. Interestingly, the other commonly
used mitochondrial KATP channel blocker, glibencamide, also
has the potential to decrease fatty acid oxidation by inhibition of
palmitoyl carnitine transferase [215–217].
Overall, the specificity of the mitochondrial KATP channel
openers and blockers is poor and the ability of several of the
KATP channel openers used to act as uncouplers or inhibitors of
respiration is especially worrying. This is because it is well
established that bona fide respiratory chain inhibitors [31,218–
221], succinate dehydrogenase inhibitors [222] and uncouplers
[223,224] are all cardio-protective when applied before or
during ischaemia even though they have no effects on
mitochondrial KATP channels. Thus, in order to establish a
role for mitochondrial potassium channels in ischaemic
preconditioning more direct evidence for their opening during
IP must be provided.
9.2. Direct measurements of mitochondrial KATP channel
activation during preconditioning
Two approaches can be taken to investigate whether mito-
chondrial K+ channel opening is occurring during precondition-ing. The first is the determination of matrix volume in situ and
the second is measurement of other effects that an increase in
electrogenic potassium flux into the matrix might have on
mitochondrial function within the cell.
9.3. Measuring matrix volume in situ
Although measurement of mitochondrial volume in situ in
the perfused heart is not possible we have determined matrix
volume in mitochondria isolated very rapidly from the perfused
heart [206]. Our data showed a significant increase in matrix
volume induced by both IP (35%) and by 50 μM diazoxide
(50%) which is consistent with the opening of a mitochondrial
KATP channel. However, 100 μM 5HD, the putative mitochon-
drial KATP channel blocker, also induced an increase in matrix
volume (50%) and failed to prevent the increase induced by IP.
Indeed, we found no correlation between matrix volume (pre-
ischaemic, end ischaemic or during reperfusion) and the
haemodynamic recovery of the heart [206]. Sollott et al. [97]
have used a sophisticated Fourier analysis of transmitted optics
linescan imaging with a 633-nm laser in isolated cardiac
myocytes to estimate changes in mitochondrial diameter from
which they calculate changes in matrix volume. They report a
2.5–4% increase in matrix volume with 30 μM diazoxide and
50 μM pinacidil consistent with opening of mitochondrial KATP
channels. However, their approach makes the assumption that
changes in diameter necessarily mean a change in matrix
volume, but as noted above (Section 8.2), this is not necessarily
the case. Furthermore, Sollott et al. report that a wide variety of
other agents known to protect hearts from reperfusion injury
through quite distinct mechanisms, including cyclosporin A, the
sarcolemmal sodium proton antiport inhibitor Hoe694 and
ligands of G protein–coupled receptors such as bradykinin and
Tyr-D-Ala-Gly-Phe-D-Leu also cause similar increases in
matrix volume [97]. They propose that such an increase in
matrix volume is critical for providing a memory that allows
protection even after removal of the primary stimulus. Their
explanation as to how this is achieved is that swelling increases
the threshold at which ROS induce the permeability transition.
However, why this should be the case is unclear since
measurements on isolated mitochondria have demonstrated
that MPTP opening is enhanced at higher matrix volume [225].
Overall, the published data on measurements of mitochondrial
volume in situ provide no strong evidence either for or against
the opening of mitochondrial K+ channels.
9.4. Measuring flavoprotein oxidation
Another approach used to investigate the activity of
mitochondrial K+ channels in cardiac myocytes is based on
the reasoning that if a K+ channel is opened the entry of K+
would cause depolarisation of the mitochondrial membrane
potential. Marban and colleagues reported that with diazoxide
this can be detected indirectly in rabbit cardiac myocytes by an
oxidation of mitochondrial flavoproteins that is reversed by
5HD [226]. Similar effects have been reported in guinea pig
myocytes using NS1619 to open the putative mitochondrial KCa
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workers have failed to reproduce the effects of diazoxide and
5HD in guinea pig and rat cardiac myocytes leading to the
suggestion that the effects observed may reflect substrate
deprivation [209,228]. In addition, there are theoretical reasons
to question whether opening of the mitochondrial KATP channel
would cause a significant depolarisation. Indeed, Garlid has
argued convincingly that the fluxes of K+ predicted to occur if
the channel opens would allow minimal perturbation of the
membrane potential even when giving a significant increase in
matrix volume [169,229]. In fact, such an increase in matrix
volume might even increase membrane potential as a result of
stimulating the respiratory chain itself [182]. Direct measure-
ments of membrane potential with the fluorescent dyes TMRE
or JC-1 failed to detect either an increase or decrease [228,230].
There are, however, other mechanisms by which changes in
mitochondrial membrane potential and thus flavoprotein
oxidation could be induced by putative mitochondrial K+
channel openers and blockers that reflect other non-specific
sites of their action. For example, in substrate deprived
myocytes where diazoxide has been shown to cause flavopro-
tein oxidation, this could be caused by the drug inhibiting
succinate dehydrogenase and thus the citric acid cycle whilst the
ability of 5 HD to overcome this effect might be the result of the
drug acting as a respiratory substrate as noted above (Section
9.1 and [12]).
10. Proposed mechanisms by which opening of
mitochondrial K+ channels might protect hearts
from ischaemia reperfusion injury?
For mitochondrial K+ channels to play a role in precondi-
tioning there would have to be a mechanism by which their
opening might be linked to improved recovery. Several possible
mechanisms have been proposed.
10.1. Enhanced mitochondrial ATP production
It is known that an increase in matrix volume can stimulate
respiration and oxidative phosphorylation [182,198] and so
might improve ATP production during reperfusion leading to
enhanced haemodynamic recovery [161,231]. Although we
were able to measure an increase in mitochondrial volume and
rates of ADP-stimulated respiration in mitochondria isolated
from hearts immediately following ischaemic preconditioning
or diazoxide treatment, the effects were largely lost during
reperfusion when they are predicted to be most important [206].
Furthermore, 5HD-treatment was shown to exhibit a similar
increase in matrix volume but was not cardioprotective [206].
Garlid and colleagues have proposed an alternative, but not
unrelated mechanism in which it is the maintenance of the
intermembrane space and the close association between the
outer an inner membrane that is the critical factor resulting from
KATP channel opening [11]. They argue that during ischaemia
the loss of membrane potential would decrease electrogenic K+
entry into mitochondria and that this would cause contraction of
the matrix. It is proposed that that this would disrupt theinteraction between VDAC in the outer membrane, octomeric
creatine kinase (CrK) in the intermembrane space and the ANT
in the inner membrane leading to faster permeation of ATP
through VDAC into the intermembrane space. Further translo-
cation of this ATP into the matrix through the ANT would lead
to its hydrolysis, that would be detrimental to the heart. It is
suggested that opening of the mitochondrial KATP channel
would prevent this matrix condensation and so decrease ATP
breakdown during ischaemia leading to less damage. There is
some evidence that ATP decline during ischaemia is slowed by
ischaemic preconditioning or diazoxide treatment, although the
mechanism originally proposed was through inhibition of the
F1Fo ATPase by enhanced binding of the ATPase inhibitor
protein [232,233]. Furthermore, other data report the opposite
effect of preconditioning, with the decline in ATP and the
development of contracture being faster than in control hearts
[232–235]. Garlid and colleagues further propose that during
reperfusion, keeping the mitochondrial KATP channel open
maintains the VDAC, CrK, ANT complex which is vital to
export ATP rapidly from the mitochondria to the cytosol where
it is used to drive contraction. Although this may be true, our
own data showed that the slight increases in matrix volume of
diazoxide-treated and ischaemic preconditioned hearts com-
pared to control hearts was not significant at reperfusion [206].
The more probable determinant of the efficiency of myocardial
ATP production during reperfusion is the extent to which the
mitochondria are damaged.
10.2. Mild uncoupling leads to less calcium overload and ROS
production
It has been proposed that opening of K+ channels would
depolarise the mitochondria sufficiently during reperfusion to
reduce ROS production and calcium accumulation and hence
prevent MPTP opening [12,151,152,162,163,227,236]. How-
ever, as noted above, the amount of depolarisation predicted
from K+ channel opening is unlikely to cause much if any
depolarisation [169,229] and this is confirmed by direct
measurements of mitochondrial membrane potential that failed
to detect any depolarisation [228,230]. Furthermore, should
significant depolarisation occur at reperfusion, ATP synthesis
would be compromised leading to poorer rather than better
recovery of the heart. Yet NMR spectroscopy measurements
have shown that the bioenergetic state of the preconditioned
heart improves during reperfusion, consistent with the better
haemodynamic function [232,237,238]. Nevertheless, it is not
possible to rule out the possibility that opening of mitoKATP
channels might cause a minor depolarisation during reperfu-
sion, or slightly reduce the repolarisation, sufficient to reduce
ROS formation without having a significant effect on ATP
production.
Although significant uncoupling during the reperfusion
phase seems unlikely to be protective, it is known that adding
low doses of uncoupler prior to ischaemia can precondition
hearts [223,224]. Indeed, any interference with oxidative
phosphorylation during the preischaemic phase seems able to
exert a similar protective effect whether it is brought about by a
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chain inhibitor [218–221] or a succinate dehydrogenase
inhibitor [222]. Since many of the putative mitochondrial K+
channel openers have also been shown to have direct uncoup-
ling effects [209–211,239] or to inhibit components of the
respiratory chain including succinate dehydrogenase [169,206–
209,240], this provides a common mode of action for these
agents. How this might be translated into a protective effect at
reperfusion is not clear, although a signalling pathway involving
AMP-activated protein kinase provides one possibility as
discussed above (Section 6.4). Another potential mechanism
would be through increased levels of ROS production causing
PKC activation and respiratory chain inhibitors such as
antimycin are known to increase ROS production which is
critical in mediating its protective effects [218,241]. It has also
been reported that low doses of uncoupler can increase ROS
production in isolated myocytes [224], although how this
might occur is unclear since in isolated mitochondria it is well
established that even very modest uncoupling greatly decreases
ROS production [242]. In the case of antimycin, PKCε
translocation has been demonstrated and its protective effects
shown to be abolished in PKCε knockout mice supporting a
role for ROS and PKCε activation in its protective mechanism
[241].
10.3. Production of ROS as a signalling mechanism
Some groups have shown that diazoxide and other putative
mitochondrial potassium channel openers cause an increase in
ROS production by isolated heart mitochondria, cardiac
myocytes and perfused hearts and that this can be blocked by
5HD [240,243–248], but this has not been reproduced in other
studies [249,250] or in our own unpublished experiments. Since
the protective effects of diazoxide and nicorandil can be
overcome by free radical scavengers such as N-(2-mercapto-
propionyl) glycine [12,100,240,245] it has been concluded by
many workers that opening of the KATP channel causes ROS
production and that this signals preconditioning through the
pathways discussed above. Attractive though this hypothesis
may be, it is difficult to formulate a mechanism by which this
might occur. As noted above, even if there were modest
uncoupling, this would be predicted to decrease ROS produc-
tion rather than increase it. Another possible mechanism would
be via an increase in matrix volume causing a stimulation of
electron flow from complex 1 into complex 3 [182,251].
Indeed, there are reports that low doses of valinomycin can
increase ROS formation in isolated mitochondria [248] and
myocytes [11,163,247], whilst pretreatment of the perfused
rabbit heart with valinomycin substantially decreased the infarct
size on reperfusion [252]. However, in our own unpublished
experiments (H. Buckman and A.P. Halestrap, unpublished
data) we have used Amplex Red to measured ROS production
by isolated heart mitochondria incubated with a variety of
respiratory substrates in State 4 and were unable to detect an
increase in ROS production with any mitochondrial potassium
channel opener tested, or when matrix volume was increased by
decreasing the osmolarity of the incubation medium. Indeed, inthe latter case we actually detected a decrease ROS production.
This is consistent with the major locus of ROS production being
at a highly reduced site on complex 1 that is oxidised by an
increase in matrix volume as electron flow out of complex 1 and
into complex 3 is stimulated [182,251].
Another consequence of opening a mitochondrial K+
channel would be an increase in the mitochondrial pH gradient
coincident with a decrease in membrane potential [253].
Whereas the latter would be predicted to decrease ROS
formation as outlined above, there is evidence to suggest than
an increase pH gradient or matrix pH can increase ROS
formation from complex 1 [254]. However, in view of the
ability of many of the mitochondrial KATP channel openers to
inhibit components of the respiratory chain [169,206–209,240],
its is perhaps more likely that their ability to increase ROS is
through a direct interaction with a redox centre in one of the
respiratory complexes.
11. Other proposed mechanism for inhibiting the
permeability transition pore in preconditioning
11.1. The role of connexin 43
Recently, it has been proposed that connexion 43 (Cx43)
may play a critical role in linking preconditioning to the
mitochondria [255–258]. Cx43 is the major protein of the gap
junction with hexameric assemblies forming connexons on
adjacent cardiomyocytes. Its traditional role is to provide a route
for intercellular communication through the propagation of
action potential, signalling molecules and metabolites [258–
260]. The permeability of the connexons can be regulated
through many mechanisms including changes in [Ca2+], pH and
phosphorylation by several protein kinases [258,259], including
PKCε and PKG, both of which have been implicated in IP as
noted above (see Section 6). Cx43 is normally partially
phosphorylated with low conductance, but progressive depho-
sphorylation occurs during ischemia causing increased con-
ductance. It has been proposed that this is important in
propagating injury from one cell to another, although hearts
from Cx43-deficient mice showed no difference in their
sensitivity to reperfusion injury [261]. Studies in both pig and
rat hearts demonstrated that the dephosphorylation of Cx43 and
electrical uncoupling during ischaemia were prevented by IP in
a PKC-dependent manner and that IP increased the co-
localization of several protein kinases with Cx43 during
ischemia [262,263]. Furthermore, hearts from Cx43-deficient
mice showed no protection from reperfusion injury by either IP
[261] or diazoxide [247] and in the latter case the ability of
diazoxide to increase ROS was also abolished.
These data imply a link between Cx43 and preconditioning
and thus that Cx43 can in some way influence the opening of
the MPTP, perhaps by a signalling mechanism involving ROS.
Recent work has suggested that this may be through a
translocation of Cx43 to the mitochondria following precondi-
tioning [255–257]. A small fraction of Cx43, primarily in its
phosphorylated form, was detected in purified mitochondria
from rat, mouse, pig and human hearts and this was increased
Fig. 4. Connexin 43 does not translocate to mitochondria following
preconditioning. Percoll purified mitochondria were isolated from control and
IP hearts in buffer containing protease and phosphatase inhibitors as described
for Figs. 1 and 2. A total particulate and cytosol fraction were also prepared by
centrifugation for 45 min at 150,000×g. For Panel A, samples were subject to
SDS-PAGE and Western blotting using the antibodies indicated. The inset blot
shows greater MCT1 contamination in mitochondria prepared according to the
method used by Boengler et al. [255]. Panel B shows the data (mean±S.E.M.)
from 6 separate experiments in which the Cx43 and ANT blots were scanned
and the Cx43 band intensity expressed as a ratio with respect to the ANT band
intensity for mitochondrial and particulate fractions.
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were taken to show that this Cx43 was not just the result of
sarcolemmal contamination of the mitochondrial fraction and
further evidence for this was provided by immunofluorescence
confocal microscopy and immuno-gold electron microscopy.
Furthermore, sub-fractionation of mitochondrial compartments
led the authors to conclude that Cx43 is translocated to the inner
mitochondrial membrane, although some Cx43 may remain
associated with the outer membrane [257].
Although we have been able to detect Cx43 in purified
mitochondria, and in preliminary experiments show that this
was increased following preconditioning, we have expressed
reservations about the likelihood of Cx43 translocation to the
inner mitochondrial membrane [256]. Furthermore, following
more extensive experiments in which we determined the extent
of sarcolemmal contamination of mitochondria by measuring
the presence of MCT1, we were unable to confirm any consis-
tent increase in the Cx43 associating with the mitochondrial
fraction following IP (Fig. 4). Thus the relevance of Cx43
translocation to the mitochondria remains uncertain, although
the loss of preconditioning in Cx43-deficient hearts from mice
argues strongly for some pool of Cx43 playing a critical role
[247,261]. Since myocytes from the Cx43-deficient mice did
not show any diazoxide-induced ROS formation [247], this is
likely to involve a ROS-mediated signalling pathway, although
the mechanism linking Cx43 to ROS production is unclear.
From their data, Garcia-Dorado and colleagues propose that
recruitment of Cx43 to the mitochondria in IP might be
required for opening of the mitochondrial KATP channel leading
to ROS production that triggers preconditioning [255,257].
However, when they prevented this recruitment with geldana-
mycin, a blocker of heat shock protein 90-dependent protein
translocation across the outer mitochondrial membrane, the
cardioprotective effects of IP were not lost [257]. Furthermore
the cardioprotective effects of both diazoxide and isoprenaline
were not accompanied by translocation of Cx43 to the
mitochondria [257]. Thus the balance of evidence suggests
that Cx43 translocation to mitochondria is not essential for
preconditioning [256].
11.2. Transient MPTP opening
Hausenloy and colleagues have reported that when the
MPTP inhibitors CsA or SfA are present during IP or
preconditioning induced by uncoupler and diazoxide, cardio-
protection is abolished [121]. They conclude that transient
opening of the MPTP may play a critical role in triggering
preconditioning and that this might be caused by the well-
documented rise in ROS that occurs during preconditioning (see
Section 6.1). However, we have challenged these conclusions
both on theoretical and experimental grounds [264]. First, our
own data using the mitochondrial 2-deoxyglucose entrapment
technique failed to detect any increase in MPTP opening
immediately following the preconditioning stimulus [68,75].
Second, although the authors suggest that transient MPTP
opening during the preconditioning phase prevents mitochon-
drial calcium overload and that this mediates protection, it is thecalcium overload at the end of ischaemia and during reperfusion
that mediates the MPTP opening responsible for reperfusion
injury. Third, the authors argue that uncoupler also precondi-
tions hearts by opening the MPTP, but uncouplers will
depolarize mitochondria independently of MPTP opening.
Thus any protection mediated by uncoupler that involves a
decrease in mitochondrial calcium loading should be insensitive
to both SfA and CsA, but this is not what the authors observed
[121]. Hence it seems probable that CsA and SfA are
overcoming IP independently of any effects on MPTP opening.
This might involve roles for cyclophilins in the preconditioning
signalling pathway similar to those responsible for the immuno-
suppressive actions of these drugs [264].
12. Conclusions and future directions
The ability of preconditioning (and post-conditioning) to
inhibit the opening of the MPTP during reperfusion and so
provide cardioprotection seems to be well established. What
is less clear is the mechanism(s) by which this is achieved.
We end this review by presenting our own views on how
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summarised schematically in Fig. 5.
The observation that mitochondria isolated immediately after
the preconditioning protocol show no protection from MPTP
opening [85,100] argues against a signalling pathway that
causes phosphorylation of some regulatory component of the
MPTP as an early event. Nor have we been able to observe any
consistent migration of protein kinases to the mitochondria or
changes in phosphorylation of a mitochondrial protein (see
Sections 6 and 7.1). By contrast, mitochondria isolated at the
end of ischaemia or during reperfusion do show a decreased
sensitivity to calcium-mediated MPTP opening [99–101]. Here
too we were unable to detect consistent migration of protein
kinases to the mitochondria or changes in phosphorylation of a
mitochondrial protein, arguing against this protection being
mediated by phosphorylation (see Section 7.1). However, the
changes in sensitivity of the MPTP do correlate with the extent
of protein carbonylation, a surrogate indicator of the oxidative
stress the mitochondria have experienced [100,101]. Since it is
well established that oxidative stress sensitises the MPTP to
calcium, this would seem to provide an adequate explanation as
to how preconditioning inhibits MPTP opening at reperfusion
(see Section 7.2). Furthermore, this is entirely consistent with
the decrease in ROS production late in ischaemia and during
reperfusion that has been observed directly in preconditioned
hearts [27,265].
If this explanation is correct then the focus of research should
shift towards investigating the mechanisms underlying the
decreased levels of ROS seen in preconditioned hearts at the end
of ischaemia and during reperfusion. This will involve
consideration of both the sources of ROS, which may includeFig. 5. Suggested pathways by which IP, KATP channel openers and other factors that
reperfusion. The proposed scheme is based on the evidence and reasoning presented i
pastel green represent components of potential signalling pathways and pastel pink t
process that perturbs mitochondrial function such as through mild inhibition of respira
PKC to diminished ROS levels at the end of ischaemia and during reperfusion targe
requires elucidation.mitochondria, NAD(P)H oxidase or xanthine oxidase, and the
pathways that remove them including superoxide dismutase,
glutathione peroxidase and catalase [26,28]. The many signal-
ling pathways identified as potential mediators of precondition-
ing, including ROS, PKCε and PKG (see Section 6) may
converge on one or more of these steps to decrease ROS levels
and hence reduce activation of the MPTP by thiol oxidation.
The pharmacological agents used to implicate these pathways
may interact specifically with their proposed target, but theymay
also have less specific effects such as on mitochondrial
respiratory chain components (see Section 9.1) to produce a
modest increase in ROS levels that stimulate signalling
pathways rather than cause damage. Indeed, it does seem that
any stress to the myocyte's energy status, be it through respira-
tory chain inhibition, uncoupling or ischaemia, causes precon-
ditioning. This may also implicate the energy sensing protein
kinase, AMP-activated protein kinase (AMPK) [133,266], in the
signalling pathway of preconditioning, and there are data
supporting such a role for AMPK in both the heart [101,135]
and the liver [267].
In addition to the protection seen early in reperfusion that
could be explained through the mechanisms described above,
there is good evidence for ongoing protection against MPTP
opening being important as reperfusion progresses. Thus
inhibition of MPTP opening with CsA or SfA provides effective
cardioprotection, as measured by decreased infarct size, even if
the drug is not present at the start of reperfusion, provided it is
added within the first 15 min [90,91]. Furthermore, there is a
considerable body of evidence to suggest that activation of
survival kinase pathways during reperfusion is critical for
protection during this phase of the insult, and that these mayperturb mitochondrial function may lead to inhibition of MPTP opening during
n the text. Boxes shaded pastel blue represent the preconditioning stimuli, whilst
he effects on the mitochondrial target. The blue box signifies the effects of any
tory chain complexes or uncoupling. The red circle and question mark that links
t represent a critical step in preconditioning whose mechanism is unknown and
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[97,107,126]. It is possible to bring these observations together
by invoking the established phenomenon of MPTP-induced
ROS production [268,269]. Once MPTP opening has occurred
during the initial phase of reperfusion, the resulting ROS
production would lead to a progressive increase in pore opening
in other mitochondria and thus an escalating number of necrotic
cells as reflected in the ongoing LDH release and increased
infarct size. CsA or SfAwill prevent this ongoing opening, but so
too might the survival kinase cascades by reducing the ROS
production or increasing their removal as described below.
It is well established that MPTP opening causes mitochon-
drial swelling and rupture of the outer mitochondrial membrane
[44]. This leads to release of pro-apoptotic factors including
cytochrome c, that activates caspase 9 and hence caspase 3 [45].
In addition, it has been shown that the pro-apoptotic factor Bax
can translocate to the mitochondria during ischaemia [72] and
this, in conjunction with cleaved Bid (tBid), might cause the
cytochrome c release observed during prolonged ischaemia [70]
despite there being no evidence of MPTP opening [68,98]. The
resulting loss of cytochrome c will slow electron transfer out of
complex 3 and thus potentially cause increased ROS production
in either complex 3 or in complex 1. An additional mechanism
that may lead to increased ROS production during ischaemia
and reperfusion is through caspase 3 mediated cleavage of the
p75 component of complex 1 [270,271]. Protection from the
rise in ROS that accompanies such cytochrome c release could
be mediated by survival kinase cascades in two ways. They
might stimulate ROS removal as described above for the
ischaemic phase or they could reduce the Bax-induced
cytochrome c release. Indeed, it is well established that survival
kinases can block apoptosis by inhibiting cytochrome c release
[272]. This is brought about by Akt-mediated phosphorylation
of the pro-apoptotic Bcl-2 family member Bad [273,274]
and, via GSK3 phosphorylation and stabilisation of the anti-
apoptotic Bcl-2 family member Mcl-1 [275].
Note added in proof
Since submission of this article it has been reported that the
properties of the mitochondrial permeability transition pore in
mitochondria devoid of all VDAC isoforms are the same as
in mitochondria from wild-type mitochondria (C.P. Baines,
R.A. Kaiser, T. Sheiko, W.J. Craigen, J.D. Molkentin, Voltage-
dependent anion channels are dispensable for mitochondrial-
dependent cell death, Nat Cell Biol. 9 (2007) 550–555). This
confirms that VDAC is not an essential component of theMPTP.
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